TW201825095A - 包含n-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之局部醫藥調配物 - Google Patents

包含n-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之局部醫藥調配物 Download PDF

Info

Publication number
TW201825095A
TW201825095A TW106141481A TW106141481A TW201825095A TW 201825095 A TW201825095 A TW 201825095A TW 106141481 A TW106141481 A TW 106141481A TW 106141481 A TW106141481 A TW 106141481A TW 201825095 A TW201825095 A TW 201825095A
Authority
TW
Taiwan
Prior art keywords
methyl
thiazol
phenyl
pyridyl
formulation
Prior art date
Application number
TW106141481A
Other languages
English (en)
Chinese (zh)
Inventor
姚傑西華 貝琪海薇
威爾佛瑞德 史其華柏
愛立克瑟登 比爾克曼
塔馬拉 普費夫
Original Assignee
德商艾庫里斯抗感染治療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商艾庫里斯抗感染治療有限公司 filed Critical 德商艾庫里斯抗感染治療有限公司
Publication of TW201825095A publication Critical patent/TW201825095A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW106141481A 2016-11-28 2017-11-28 包含n-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之局部醫藥調配物 TW201825095A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16201005 2016-11-28
??16201005.2 2016-11-28

Publications (1)

Publication Number Publication Date
TW201825095A true TW201825095A (zh) 2018-07-16

Family

ID=57406185

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106141481A TW201825095A (zh) 2016-11-28 2017-11-28 包含n-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之局部醫藥調配物

Country Status (4)

Country Link
AR (1) AR110250A1 (es)
TW (1) TW201825095A (es)
UY (1) UY37497A (es)
WO (1) WO2018095576A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4209491A1 (en) 2017-10-05 2023-07-12 Innovative Molecules GmbH Enantiomers of substituted thiazoles as antiviral compounds
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
EP3925595A1 (en) * 2020-06-17 2021-12-22 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate
EP4096632A1 (en) 2020-03-26 2022-12-07 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate
CN116134038A (zh) * 2020-06-30 2023-05-16 德米拉公司 Irak4抑制剂及其局部用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10129716A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
AU2011275458B2 (en) * 2010-07-08 2014-11-27 Devirex Ag Polyethylene glycol compositions for controlling relapse of herpes labialis, herpes genitalis, and herpes zoster
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Also Published As

Publication number Publication date
UY37497A (es) 2018-06-29
AR110250A1 (es) 2019-03-13
WO2018095576A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
TW201825095A (zh) 包含n-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之局部醫藥調配物
US10137140B2 (en) Therapeutic composition
Grampurohit et al. Microemulsions for topical use–a review
KR101734424B1 (ko) 난용성 화합물의 용해도를 증가시키는 방법과 이와 같은 화합물의 제형을 제조하는 방법 및 사용하는 방법
EP2191828B1 (en) Antifungal pharmaceutical composition
ES2604160T3 (es) Composiciones y métodos para la administración tópica de prostaglandinas en la grasa subcutánea
KR101926211B1 (ko) 이부프로펜의 경피 조성물들 및 이의 이용 방법들
JP6105475B2 (ja) 可溶性の乏しい化合物の可溶性を増大させる方法ならびにそのような化合物の配合物を作る、および用いる方法
US20170182071A1 (en) Tetracycline topical formulations, preparation and uses thereof in treating an ocular condition
US20130116271A1 (en) Tacrolimus-containing oil-in-water type creamy composition
CN110049764A (zh) 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
JP2010502764A (ja) テルル含有化合物の局所製剤
CN104411303A (zh) 用于治疗皮肤炎性疾病的方法
US20160081901A1 (en) Compositions and methods for hair growth
AU2009256524B2 (en) Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
KR20210065968A (ko) 심미적 피부 상태를 치료하기 위한 철 킬레이팅 화합물
KR20190089852A (ko) 4-메틸-5-(피라진-2-일)-3h-1,2-디티올-3-티온의 제제, 및 그의 제조 및 사용 방법
JP5338030B2 (ja) アダパレン含有外用剤組成物
EP4196477A1 (en) Tofacitinib-containing anhydrous elastomer-based gel formulations
CA3055881C (en) Use of heterocyclic compounds in the treatment of pigmented skin
Palma et al. Vitamin C based nanostructures: potential utility in ocular and transdermal therapy
WO2019136196A1 (en) Therapeutic composition
CA3055882A1 (en) Topical formulation for the treatment of pigmented skin
JP2018002651A (ja) 慢性角化型湿疹改善剤
WO2013111817A1 (ja) タクロリムスを含有する水中油型クリーム状組成物